Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Placebo-controlled, Double-blind Trial of the Antidepressant Efficacy of a Novel CNS-penetrant P2X7 Receptor Antagonist, JNJ-54175446, in People With Major Depressive Disorder, an Incomplete Response to Monoaminergic Antidepressant Drugs, and a Biomarker Profile Predictive of Active P2X7 Signalling

NCT04116606 is registered in ClinicalTrials.gov with CCTU-Core as lead sponsor.

NCT NCT04116606
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04116606 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Placebo-controlled, Double-blind Trial of the Antidepressant Efficacy of a Novel CNS-penetrant P2X7 Receptor Antagonist, JNJ-54175446, in People With Major Depressive Disorder, an Incomplete Response to Monoaminergic Antidepressant Drugs, and a Biomarker Profile Predictive of Active P2X7 Signalling
Lead sponsor
CCTU-Core
Phase
Phase 2
Overall status
Unknown status
Start date
September 12, 2019
Completion date
June 30, 2024
Enrollment
142 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major, inflammation